Literature DB >> 6832205

Non-linear elimination processes of theophylline.

U Gundert-Remy, R Hildebrandt, N Hengen, E Weber.   

Abstract

After intravenous and oral administration of theophylline to four healthy subjects, the plasma concentration-time curve of theophylline could be described by linear pharmacokinetics, although total clearance in all subjects decreased when the dose was increased; the doses were theophylline 193.2 mg and 386.4 mg i.v. and 161 mg and 322 mg p.o. Total clearance was 65.5 +/- 11.3 ml/min. Renal clearance changed from 15.2 +/- 9.5 ml/min in the first two hours after administration to 4.9 +/- 5.5 ml/min between 16 and 24 h (p less than 0.001). 1,3-dimethyluric acid (DMU), the major metabolite of theophylline, was determined in urine and in plasma. The renal clearance of DMU was constant at 496.7 +/- 180 ml/min. There was some evidence that at high plasma concentrations of theophylline the formation of DMU might be a zero-order process. The renal excretion rate of 1-methyluric acid (1-MU) paralleled that of DMU, which is in accordance with the assumption that DMU is demethylated to 1-MU. 3-methylxanthine (3-MX) was excreted in urine at a constant rate over 10 h, the rate being equivalent to the dose, which is contrary to the assumption of Michaelis-Menten-kinetics. 3-methyluric acid was found to be a minor metabolite of theophylline and 1-methylxanthine (1-MX) could not be detected. The cumulative amounts excreted in urine, expressed as a percentage of the dose and corrected for molecular weight, were theophylline 16.6 +/- 6.5%, DMU 44.3 +/- 7.0%, 1-MU 24.3 +/- 4.8%, 3-MX 12.9 +/- 3.4% and 3-MU 2.2 +/- 1.8%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832205     DOI: 10.1007/bf00613930

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

Review 2.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Determination of theophylline and its metabolites in human urine and serum by high-pressure liquid chromatography.

Authors:  R D Thompson; H T Nagasawa; J W Jenne
Journal:  J Lab Clin Med       Date:  1974-10

4.  Measurement of excretion characteristics of theophylline and its major metabolites.

Authors:  J H Jonkman; D Tang; R A Upton; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Simultaneous determinations by theophylline and its major metabolites in urine by reversed-phase ion-pair high-performance liquid chromatography.

Authors:  K T Muir; J H Jonkman; D S Tang; M Kunitani; S Riegelman
Journal:  J Chromatogr       Date:  1980-11-14

6.  Influence of methylxanthine-containing foods on theophylline metabolism and kinetics.

Authors:  T J Monks; J Caldwell; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

7.  Cardiovascular response to increasing theophylline concentrations.

Authors:  R I Ogilvie; P G Fernandez; F Winsberg
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

8.  Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

Authors:  D D Shen; M Fixley; D L Azarnoff
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

9.  Dose-dependent kinetics for theophylline: observations among ambulatory asthmatic children.

Authors:  E Sarrazin; L Hendeles; M Weinberger; K Muir; S Riegelman
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

10.  Dose-dependent elimination kinetics of theophylline.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

View more
  19 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  [Pharmacokinetics and pharmacodynamics of theophylline in geriatric patients with multiple diseases].

Authors:  W Mühlberg; D Platt; M Bauer; U Salzner
Journal:  Klin Wochenschr       Date:  1987-07-15

3.  Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions.

Authors:  V W Steinijans; H U Schulz; A Böhm; W Beier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways.

Authors:  S Dadashzadeh; H Tajerzaden
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

5.  Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.

Authors:  J Sato; H Nakata; E Owada; T Kikuta; M Umetsu; K Ito
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Binding of theophylline and its metabolites to human plasma proteins.

Authors:  U Gundert-Remy; R Hildebrandt
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

7.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 8.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

9.  Renal clearance of theophylline and its major metabolites: age and urine flow dependency in paediatric patients.

Authors:  I Bonnacker; D Berdel; R Süverkrüp; A von Berg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 10.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.